13 Two meta-analyses of other GLP-1 RA CVOTs found that GLP-1 RAs were associated with greater rates of DR progression, but both studies found that the effect was driven by the extent of hemoglobin A1c reduction, rather than the medications themselves
Market Challenges High Cost of Treatment Limits Adoption Across Lower-Income Populations and Health Systems Despite clinical efficacy, the high cost of GLP-1 therapies remains a significant barrier to widespread adoption
This pattern is consistent with what researchers see across the category, whether the medication targets the GLP-1 pathway or works as an amylin analog
Notably, our subgroup analysis showed greater protective effects in older adults and obese individuals, two populations already at heightened risk for gastrointestinal cancers
In a more recent study, researchers encapsulated CoQ10 into micelles and found that CoQ10-micelles had a better chondroprotective effect than CoQ10 in OA rats [177]
and Castelo-Soccio, L